COR: Specialty growth, biosimilars, and MSO expansion fuel strong performance amid stable partnerships
Specialty pharmaceuticals and oncology drive strong growth, with international operations rebounding and strategic relationships remaining stable. Minor Walgreens volume shifts were anticipated, and biosimilars, AI, and MSO expansion offer future opportunities. Independent pharmacies remain resilie…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.